DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR MAXALT
All Clinical Trials for Maxalt
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00360282 ↗ | Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines? | Completed | Merck Sharp & Dohme Corp. | N/A | 2006-08-01 | The purpose of this study is to determine if Rizatriptan, a migraine medication, lowers motion sickness in migraine sufferers. |
| NCT00360282 ↗ | Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines? | Completed | University of Pittsburgh | N/A | 2006-08-01 | The purpose of this study is to determine if Rizatriptan, a migraine medication, lowers motion sickness in migraine sufferers. |
| NCT00397254 ↗ | Two Rizatriptan Prescribing Portions for Treatment of Migraine | Completed | Merck Sharp & Dohme Corp. | Phase 4 | 2006-12-01 | The primary objective of this study is to evaluate a clinical limit (CL) of rizatriptan (9 rizatriptan 10mg Orally Disintegrating Tablet (ODT) per month) versus (vs.) a formulary limit (FL) of rizatriptan (27 rizatriptan 10mg ODT per month) as measured by the number of days of migraine per month. |
| NCT00397254 ↗ | Two Rizatriptan Prescribing Portions for Treatment of Migraine | Completed | Clinvest | Phase 4 | 2006-12-01 | The primary objective of this study is to evaluate a clinical limit (CL) of rizatriptan (9 rizatriptan 10mg Orally Disintegrating Tablet (ODT) per month) versus (vs.) a formulary limit (FL) of rizatriptan (27 rizatriptan 10mg ODT per month) as measured by the number of days of migraine per month. |
| NCT00471952 ↗ | Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2007-04-01 | The purpose of this study is to evaluate the effect of rizatriptan, alone or combined with caffeine for treating acute attacks of migraine. Each subject will have 3 months to treat 3 acute migraine headache attacks. Each subject will be dispensed one box containing 3 packets of study medication labeled for Headache #1, Headache #2, or Headache #3. Each packet wil contain either Maxalt 10mg MLT or a Maxalt placebo (sugar pill), and a capsule containing either caffeine 75mg or a capsule containing placebo (sugar). One headache will be treated with a combination of Maxalt 10mg MLT and caffeine. Another headache will be treated with a combination of Maxalt 10mg MLT and a capsule containing placebo. A third headache will be treated with just placebo. Neither the subject, the study coordinator, or your study doctor will know in which order you will receive the three different treatments. This information is available in case of emergency. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Maxalt
Condition Name
Clinical Trial Locations for Maxalt
Trials by Country
Clinical Trial Progress for Maxalt
Clinical Trial Phase
Clinical Trial Sponsors for Maxalt
Sponsor Name
